The respiratory research team at Bradford Teaching Hospitals has put itself on the map after recruiting European and global-first patients in two pioneering medical trials.
The trust says that thanks to a renowned international reputation in respiratory medicine, pharmaceutical giant GSK has chosen the Bradford Institute for Health Research (BIHR) to be the first unit worldwide to test its new vaccine for Chronic Obstructive Pulmonary Disease (COPD) patients.
The multi-centre trial aims to assess whether the vaccine offers protection against a bacterium which commonly causes a worsening in the condition of patients with COPD.
The team have also recruited a Europe-first patient in the Andhi study into severe asthma.
Dr Dinesh Saralaya, Consultant Respiratory Physician and Associate Director of Research at BIHR, said: “In this study there will be 1,000 patients recruited worldwide, and we will recruit between three and five patients.
“Our Clinical Trails Unit has recruited the first patient in the whole of Europe which is a big achievement. They have chosen Bradford because of our reputation for recruiting very well into several asthma trials in the past. But support from our research and development department has helped us achieve this.”
Six Men Convicted in Non-Recent Child Sexual Abuse Case
Average Speed Cameras Installed on Harrogate Road
Police Appeal After Serious Collision in Moss Side
Culture at the Heart of Stockport’s Transformation
South Asian Art Exhibition Opens at Cartwright Hall
Men’s Mental Fitness Programme Launches in Blackburn
Council Calls for Tougher Fly-Tipping Sentences
Free Midsummer Festival to Return to Milton Keynes
Leeds Sets Out ‘Landmark Year of Opportunity’ for Major Projects
Alim OnAir
The Golden Era
Bhangra Nights
Remix Saturdays